Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2019-10-30 Declaration of Voting R…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Evotec SE: Release according to Article 41 of the WpHG' and specifically announces the 'Publication of total number of voting rights' following a 'Conditional capital increase'. This type of announcement, dealing with changes in the total number of voting rights, is a specific regulatory disclosure. While it relates to capital structure, the core focus is the official notification of the voting rights count, which is often categorized under general regulatory announcements or specific voting rights declarations. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most precise fit for an announcement detailing the total number of voting rights, even if it's not the result of a vote, but rather the basis for future voting rights following a capital measure. However, since the document explicitly details a capital measure ('Conditional capital increase') and the resulting total voting rights, it could also relate to 'Capital/Financing Update' (CAP). Looking closely at the definitions, DVA covers 'Official results from shareholder votes at any general meeting (AGM or EGM)'. This document is not a result of a vote, but a notification under WpHG Article 41 regarding the total number of shares/rights. Since it is a mandatory regulatory disclosure concerning the capital structure/voting rights, and it doesn't fit perfectly into CAP (which is about fundraising/financing activities), the most appropriate general regulatory category for mandatory disclosures not covered elsewhere is RNS, or if we strictly interpret the content about voting rights, DVA might be considered if the scope of DVA is interpreted broadly to include the total voting rights count. Given the specific nature of WpHG Article 41 announcements regarding the total number of shares/voting rights, and the lack of a specific 'Total Voting Rights' code, RNS (Regulatory Filings) is the safest fallback for a mandatory regulatory announcement that doesn't fit the other specific categories like DIV, SHA, or DVA (which implies vote results). However, since the content is about the total voting rights count, and this is a key input for shareholder actions, I will classify it as RNS as it is a general regulatory announcement via DGAP/EQS, which is the fallback for miscellaneous regulatory filings.
2019-10-30 English
EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT
Legal Proceedings Report Classification · 99% confidence The document is a press release dated October 23, 2019, announcing a new strategic partnership (LAB555) between Evotec, Integra Holdings, and Yissum to fast-track early-stage drug development. It is structured as a news announcement, includes quotes from CEOs, and details about the involved entities. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it announces a significant business development/collaboration that doesn't fit the specific categories like M&A (TAR), Financing (CAP), or Director Dealing (DIRS), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate news announcements distributed via services like DGAP/EQS.
2019-10-23 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership, specifically mentioning 'Notification of Major Holdings' under German securities law (WpHG). Section 6 details the 'New' and 'Previous notification' percentages of voting rights held by Morgan Stanley. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds.
2019-10-22 English
Correction of a release from 30/09/2019, 14:52 CET/CEST - Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a regulatory announcement transmitted by DGAP, specifically titled 'Total Voting Rights Announcement' and includes a correction to a previous release. It details a 'Conditional capital increase' and provides the 'New total number of voting rights'. This content directly relates to changes in the company's capital structure and voting rights, which falls under the scope of capital/financing updates or voting rights announcements. Since it explicitly mentions a capital measure ('Conditional capital increase') and reports the resulting total voting rights, the most precise fit among the provided codes is 'CAP' (Capital/Financing Update) or 'DVA' (Declaration of Voting Results & Voting Rights Announcements). Given the focus on the capital measure itself (Conditional capital increase) and the resulting total rights, 'CAP' is highly relevant. However, the core purpose of this specific filing type under German law (Article 41 WpHG) is the notification of the total voting rights resulting from a capital change. 'DVA' covers 'Official results from shareholder votes at any general meeting' and 'Voting Rights Announcements'. Since this is a notification of the *total* voting rights following a capital measure, 'DVA' is a strong candidate, but 'CAP' covers the underlying action (capital increase). Looking closely at the definitions, 'SHA' (Share Issue/Capital Change) is also very relevant for a capital increase. Let's re-evaluate: 'SHA' is for 'Announcement regarding new share issues, stock splits, or other capital changes.' This document announces the consequence of a capital change (the new total voting rights). 'CAP' is for 'Updates on company fundraising, financing activities, or capital structure changes.' A conditional capital increase is a capital structure change. Given the explicit mention of 'Conditional capital increase' and the reporting of the resulting total voting rights, 'SHA' (Share Issue/Capital Change) is the most specific fit for the underlying corporate action being reported, even though it's framed as a voting rights notification. If 'SHA' is not available, 'CAP' would be the next best. Since 'SHA' is available, I select it as the primary classification for reporting the consequence of a capital change.
2019-10-11 English
JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS SIGN LICENSING DEAL FOR A BIOSIMILAR ASSET
M&A Activity Classification · 99% confidence The document is a news release dated October 10, 2019, announcing a strategic licensing agreement between Just – Evotec Biologics and Biocon Biologics for a biosimilar asset. It details the terms (license fee, milestone payments) and the strategic implications for both companies. This type of announcement, which details a significant business transaction (licensing/partnership) but is not a formal regulatory filing like a 10-K or a standard earnings release, fits best under the category of Capital/Financing Update (CAP) if it involves significant financial structuring, or more generally, a Regulatory Filing (RNS) if it's a broad corporate announcement. Since the core event is a licensing deal involving future payments and asset transfer, it relates to corporate activity and financing structure. However, given the options, 'M&A Activity' (TAR) is for mergers/takeovers, which this is not. 'Capital/Financing Update' (CAP) covers fundraising/financing activities. While this is a licensing deal, it is a major corporate transaction announcement. In the context of standard financial filings, major partnership/licensing deals that involve upfront payments and future milestones are often categorized broadly. Since there is no specific 'Partnership Announcement' code, and it's not a standard financial report, I will check if it fits 'Regulatory Filings' (RNS) as a general corporate news item disseminated via DGAP. Given the nature of the announcement—a significant business development/transaction—and the lack of a more specific code for licensing deals, RNS is the most appropriate fallback for a general corporate news release disseminated via DGAP that doesn't fit ER, IR, 10-K, or CAP (which usually implies equity/debt issuance). However, because it involves the transfer of an asset and future financial considerations, it is a significant corporate transaction. If we strictly interpret the definitions, it is a general corporate news item disseminated via DGAP, making RNS the safest classification, as it is not a formal financial report (ER, IR) or a management/board change (MANG).
2019-10-10 English
EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION
Regulatory Filings Classification · 100% confidence The document is a press release dated October 9, 2019, announcing a strategic collaboration between Evotec SE and Celmatix Inc. It details the partnership's goals (developing pre-clinical programs for women's health conditions) and the roles of each company. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement regarding a business development/partnership. Since there is no specific category for 'Partnership Announcement' or 'Business Development,' and it is not a standard financial report, the most appropriate fallback category is 'Regulatory Filings' (RNS), which often serves as a catch-all for significant, non-standard corporate news disseminated via regulatory channels (indicated by the DGAP header). The document length (8605 chars) is substantial enough that it is the primary content, not just an announcement of content.
2019-10-09 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.